Enlarge / Martin Shkreli arrives at Brooklyn Federal Court on the first day of his securities fraud trial in 2017.Getty | Kevin Hagen
In an effort to avoid being held in contempt of court, former pharmaceutical executive and convicted fraudster, Martin Shkreli, made an eyebrow-raising argument to a federal judge Friday, stating that his company Druglike, which he previously described as a “drug discovery software platform,” was not engaged in drug discovery. As such, he argued he is not in violation of his sweeping lifetime ban from the pharmaceutical industry.
Last month, the Federal Trade Commission and seven states urged
→ Continue reading at Ars Technica